Acute Kidney Injury
Patients with an eGFR below 60 mL/min/1.73 m2 were more likely to die in the hospital or be discharged to hospice.
There is a strong association between magnified nadir platelet counts and the severity of AKI.
Women with r-AKI had increased rates of preeclampsia and premature infant births, compared with controls.
The researchers found that stage 2 acute kidney injury was associated with increased risk of delirium and coma as was stage 3 acute kidney injury.
The condition also is associated with greater use of renal-replacement therapy and mechanical ventilation.
It also may shorten intensive care unit and hospital length of stay versus late RRT in critically ill patients, meta-analysis reveals.
Odds of acute kidney injury increases by 29% with each 1 mg/dL increment in uric acid level at ICU admission.
Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.
Medicine is making progress to refine patient care.
Four single-nucleotide polymorphisms at two loci identified in discovery, replication populations.
Hyperphosphatemia was associated with more than double the risk of death from any cause.
The mortality rate among patients with negative fluid balance was just 7.4%, compared with 43.5% for patients with a positive fluid balance.
Study identifies 3 biomarkers that could detect increasing risk of worsening AKI in patients with acute cardiorenal syndrome.
This approach is associated with lower urine output during the first 7 days of therapy.
NSAIDs + diuretics with or without additional renin-angiotensin aldosterone agents demonstrated the strongest level of evidence.
In a meta-analysis, AKI was associated with an 86% increased risk of CV-related death and 38% increased risk of other major CV events.
The Food and Drug Administration (FDA) announced it is strengthening the current warning about the risk of acute kidney injury for drug products containing canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).
Male gender, diabetes, and renal function decline at 90 days implicated as risk factors; patients rarely progress to end-stage renal disease.
Japanese study demonstrates a 2-fold increased risk of death from any cause.
Patients were 40% less likely to die in 2011 compared with 2001, study finds.
Study demonstrates improved 90-day survival and greater likelihood of recovering renal function.
High FiO2 and norepinephrine in AKI patients increases their risk of death within 24 hours of being placed on continuous renal replacement therapy.
Mortality no different for early versus delayed strategy for patients with severe acute kidney injury.
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
Poor long-term outcomes found even in patients with community-acquired AKI but not hospitalized.
Statins don't prevent complications and may cause acute kidney injury, researchers report.
Treatment linked to improved long-term survival, regardless of underlying kidney function.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
The addition of aliskiren to enalapril led to more adverse events in patients with chronic heart failure without an increase in benefit.
Study finds no significant difference in the rates of all-cause mortality, major cardiac events, and hospital admission with hyperkalemia or AKI.
Renal and Urology News Articles
- Novel Calcimimetic Approved for Secondary Hyperparathyroidism
- Prostate Cancer Treatment Prolongs Survival
- Misplaced Mobile Devices Lead to HHS Investigations, Millions in Fines
- PCa Salvage Radiation Plus Anti-Androgen Therapy Improves Outcomes
- Targeted Biopsy Improves Detection of Significant PCa in Black Men
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)